Diagnosis and treatment of malignant tumors using integrated traditional and western medicine: Progress, challenges and reflections

详细信息    查看全文

• 作者：Xiao-feng Zhai (1)
  Chang-quan Ling (1)
  
• 关键词：malignant tumors ; Chinese medicine ; integrated traditional and Western medicine
• 刊名：Chinese Journal of Integrative Medicine
• 出版年：2012
• 出版时间：May 2012
• 年：2012
• 卷：18
• 期：5
• 页码：333-338
• 全文大小：520KB
• 参考文献：1. Jemal A, Melissa M, Ward E. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-0. CrossRef
  2. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking Tob Control 2006;15:345-47. CrossRef
  3. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-49. CrossRef
  4. Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL. Survival of liver cancer during 2001-007 in Qidong city. Chin J Cancer Prev Treat (Chin) 2011;18:568-70.
  5. Bai CX, Zhang Y. Progress in early diagnosis of lung cancer. Natl Med J Chin 2009;89:1290-292.
  6. Li ZS. Status and prospects of early diagnosis of pancreatic cancer. Chin J Clin Hepatol (Chin) 2010;26:451-53.
  7. Zhou YQ, Li Z. Development report of traditional Chinese medicine tumor subject. Chin J Manag Chin Med (Chin) 2008;16:73-8.
  8. Li LD, Lu FZ, Zhang SW, Mu R, Sun XD, Huangpu XM, et al. Analysis about mortality of cancer in China 1990-992. Chin J Oncol (Chin) 1996;18:403-07.
  9. Zhang SW, Chen WQ, Kong LZ, Li LD, Lu FZ, Li GL, et al. An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998-002. Bulletin Chin Cancer (Chin) 2006;15:430-48.
  10. Dai M, Li N, Li Q, Yang L, Chen YH. Survey of cancer prevention and control in the world. Bulletin Chin Cancer (Chin) 2011;120:21-4.
  11. Wang ZJ, Duan JC, Guo QZ, Wei ZG, Xue WC, Wu MN, et al. A phase II clinical trial of celecoxib combined with platinum-based chemotherapy in the treatment of patients with advanced NSCLC as first-line treatment. Chin J Lung Cancer (Chin) 2008;11:425-30.
  12. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009;39:137-50. CrossRef
  13. Noro R, Gemma A. EGFR and gefitinib (Iressa). Gan To Kagaku Ryoho (Jpn) 2008;35:1076-079.
  14. Verhoef MJ, Balneaves LG, Boon HS, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 2005;4:274-86. CrossRef
  15. Correa-Velez I, Clavarino A, Eastwood H. Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med 2005;8:953-61. CrossRef
  16. Gupta D, Lis CG, Birdsall TC, Grutsch JF. The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 2005;13:912-19. CrossRef
  17. Yang HW. Present situation of the clinical researches on traditional Chinese medicine. Zhejiang J Integr Tradit Chin West Med (Chin) 2011;21:372-74.
  18. Liu JP. Evidence-based medicine approach and CM therapeutic evaluation. J Cap Univ Med Sci (Chin) 2007;28:212-15.
  19. Qing XM, Fang YG, Liu BY, Wang YY. Pragmatic randomized controlled trials and its methodological features. J Beijing Univ Tradit Chin Med (Chin) 2008;31:14-8.
  20. Wang SC, Liu JP, Li H, Yu H. Guidelines for evidence-based Chinese medicine clinical pathway report. J Chin Integr Med (Chin) 2010;8:819-23. CrossRef
  21. Ohorodnyk P, Eisenhauer AE, Booth MC. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point Eur J Cancer 2009;45:2249-252 CrossRef
  22. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008;26:5458-464. CrossRef
  23. Liu JP. Evidence-based medicine and individualized health care. J Chin Integr Med (Chin) 2009;7:505-08. CrossRef
  
• 作者单位：Xiao-feng Zhai (1)
  Chang-quan Ling (1)
  
  1. Department of Traditional Chinese Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China
  

文摘

Malignant tumors are one of the leading causes of death in the world. Considerable progresses have been made on the treatment of tumors in recent decades, especially in the prevention, early diagnosis and the model changing of therapeutics. But we are still facing tough challenges, including the increasing treatment burden and limited improvement of efficacy. In China, Chinese medicine (CM) provides a powerful arsenal to fight against tumors. CM can be well applied to the onset and progression of tumors in China, bearing the characteristics of multi-target, multi-phase and multi-effect. But there are also many problems demanding urgent attention in the use of CM. Some most debated problems in this field were summarized. We should upgrade our concepts in using CM, find its position scientifically, and establish evidence of its effect by high quality clinical research.